Natco Pharma Ltd is on its way to entering the dedicated research and development company bandwagon soon.
The Rs 207-crore active pharma ingredients (APIs) and formulations company is contemplating hiving off its R&D division into a separate outfit.
"Natco, which has already found promising results from two of its new chemical entities (NCEs), has decided to take up the entire R&D activities by a separate corporate entity," its Director and Chief Financial Officer, Mr P. Bhaskara Narayana, said.
According to him, the key idea is to de-risk the company from the uncertainties of the success of these molecules, apart from the high costs associated with filing of investigative new drug application (IND) for these molecules.
"Natco, which has already found promising results from two of its new chemical entities (NCEs), has decided to take up the entire R&D activities by a separate corporate entity," its Director and Chief Financial Officer, Mr P. Bhaskara Narayana, said.
